Top Industry Leaders in the Chronic Obstructive Pulmonary Disease (COPD) Market
Latest Chronic Obstructive Pulmonary Disease Treatment Companies Update
Teva's ArmonAir Digihaler approved this inhalation powder device with built-in sensors and a companion app in February 2022, aiming for better medication adherence in COPD patients.
GlaxoSmithKline's Trelegy Ellipta Launched in India in April 2022, this once-daily single-inhaler triple therapy offers a convenient option for COPD patients requiring multiple medications.
NextCure's VSTM-1 Targeting Antibody promising therapy in Phase 2 clinical trials aims to treat inflammatory lung diseases like COPD by activating an immune cell protein.
Multiple clinical trials underway Several companies are exploring novel drug targets and treatment approaches for COPD, focusing on improved symptom management, disease progression prevention, and potential cures.
List of Chronic Obstructive Pulmonary Disease Treatment Key Companies in the Market
-
AstraZeneca (UK)
-
Abbott Laboratories (US)
-
Dr. Reddy’s Laboratories Ltd (India)
-
GlaxoSmithKline (UK)
-
F. Hoffmann-La Roche Ltd (Switzerland)
-
Almirall (Spain)
-
Boehringer Ingelheim (Germany)
-
Pfizer Inc. (US)
-
Novartis AG (Switzerland)
-
Astellas Pharma (Japan)